CannaPharmaRX（CPMD）株式概要CannaPharmaRX, Inc.は、カナダにおける大麻栽培施設の買収、開発、運営に従事している。 詳細CPMD ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 US市場と比較して、過去 3 か月間の株価の変動が非常に大きいキャッシュランウェイが1年未満である 意味のある時価総額がありません ( $2M )+1 さらなるリスクすべてのリスクチェックを見るCPMD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.00396.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-29m32m2016201920222025202620282031Revenue US$31.9mEarnings US$4.7mAdvancedSet Fair ValueView all narrativesCannaPharmaRX, Inc. 競合他社Avenue TherapeuticsSymbol: OTCPK:ATXIMarket cap: US$988.4kBespoke ExtractsSymbol: OTCPK:BSPKMarket cap: US$2.1mIterum TherapeuticsSymbol: OTCPK:ITRM.FMarket cap: US$2.4mGelStatSymbol: OTCPK:GSACMarket cap: US$748.1k価格と性能株価の高値、安値、推移の概要CannaPharmaRX過去の株価現在の株価US$0.00352週高値US$0.0152週安値US$0.0003ベータ-1563.371ヶ月の変化-23.08%3ヶ月変化0%1年変化-9.09%3年間の変化-71.15%5年間の変化-98.12%IPOからの変化-99.90%最新ニュースお知らせ • Jan 14Cannapharmarx, Inc. Announces Resignation of Director Rick Orman, Effective January 8, 2026CannaPharmaRX, Inc. announced that on January 8, 2026, Rick Orman informed the Board of Directors of his resignation as a member of the Board effective immediately. Mr. Orman's resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company.お知らせ • Aug 22Cannapharmarx, Inc. Announces Revenue Guidance for Third Quarter 2025CannaPharmaRX, Inc. announced revenue guidance for third quarter 2025. The company projects revenues of approximately CAD 1,050,000, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate.お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jun 06CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/15/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Jan 14Cannapharmarx, Inc. Announces Resignation of Director Rick Orman, Effective January 8, 2026CannaPharmaRX, Inc. announced that on January 8, 2026, Rick Orman informed the Board of Directors of his resignation as a member of the Board effective immediately. Mr. Orman's resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company.お知らせ • Aug 22Cannapharmarx, Inc. Announces Revenue Guidance for Third Quarter 2025CannaPharmaRX, Inc. announced revenue guidance for third quarter 2025. The company projects revenues of approximately CAD 1,050,000, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate.お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jun 06CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/15/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 28CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/27/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2023, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 15CannaPharmaRX, Inc. Announces Executive ChangesEffective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc. effective June 1, 2023. There was no disagreement between and Mr. Cassels on any matter related to operations, policies or practices that led to Mr. Cassels’s replacement as CFO. Effective October 13, 2023, Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer. Mr. Foeste has consented to such appointment. Mr. Foeste is the founder and Managing Partner of Invictus Accounting Group LLP and has significant executive, director, finance, and public company compliance experience across a number of industry sectors including cannabis and nutraceuticals. Prior to Invictus, Mr. Foeste was in senior finance and accounting roles at TSX, TSXV, and NYSE listed issuers, and earned his CPA at Deloitte and a boutique tax advisory firm.お知らせ • Aug 26CannaPharmaRx Expands Board of DirectorsCannaPharmaRX, Inc. announced that it has expanded its board of directors from three seats to five. The board deemed this expansion was in the best interest of the corporation as it coincides with an expansion of operations. The following person(s) were elected to the Board to fill the newly created directorships until the next annual meeting of stockholders of the corporation: Mr. Anthony Panek, age 38, is a corporate mergers and acquisitions attorney and venture capital investor with expertise in capital raising formation and growing businesses. He has worked with private equity and venture capital funds to allocate capital to emerging growth companies and works with emerging growth companies, both public and private, to raise capital and acquire assets and corporate talent. He has been an investor in many emerging growth companies and private funds investing in similar companies. He works with companies from a business and legal perspective to navigate and manage growth challenges facing emerging growth companies and helping companies complying with their SEC reporting obligations. He completed the Venture Capital Certificate Program at Startup@Berkeley Law. Mr. Panek was selected to serve on the Company's Board based upon his experience as an attorney and venture capital and private equity investor helping emerging companies raise capital, comply with SEC reporting and governance requirements, and his work with other cannabis companies. Mr. Adam Mindle, age 52, is a transactional attorney with extensive experience in structuring, negotiating and documenting sophisticated joint ventures, secured financing and mergers and acquisitions related to real estate, healthcare and technology companies. In 2010, Mr. Mindle co-founded Greystone Law Group LLP. Prior to co-founding Greystone Law Group LLP, Mr. Mindle was a partner in the Los Angeles officer of Orrick, Herrington & Sutcliffe LLP. Mr. Mindle is a veteran authority on real estate, finance and corporate transactions having represented real estate developers, private equity funds, pension funds, REITs, public and private companies and institutional lenders in connection with the acquisition and disposition of real estate assets, secured financing and joint ventures. During his three-decade career, Mr. Mindle has guided numerous start-up companies, mature organizations, pension funds, REITs and other public and private companies through a myriad of sophisticated transactions valued in billions of dollars. The third and final board position will look to be filled in the near future. Mark Branson has chosen to step down from his current position on the Board.お知らせ • Jun 24CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.お知らせ • Jan 12CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million ExpectedCannaPharmaRx, Inc. announced that it has received its CRA license. A company can start producing cannabis products after receiving licensing from both the CRA and Health Canada. CannaPharmaRx can now begin business activities relating to the production and sale of cannabis. The license is valid for up to two years. CannaPharmaRx is now authorized to grow cannabis and sell wholesale to other licensed producers throughout Canada. The CRA oversees regulation of cannabis products including the production, possession, removal, sale and distribution of cannabis as well as impose proper excise duties and taxes on cannabis products. Now that both licenses are approved the company anticipates completing the first harvest during the current quarter with estimated annual revenue over $30 million.お知らせ • Dec 22+ 2 more updatesCannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 MillionCannaPharmaRx, Inc. announced Health Canada has issued a cultivation license to the Company. As a result, CannaPharmaRx may now legally grow cannabis and sell its crop to other licensed producers and licensed wholesalers throughout Canada. Health Canada is the department of the federal government of Canada responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. The new license, denominated LIC-3JCQW6DIU0, is among the final major steps prior to production. This type of standard cultivation license is a prerequisite for licensed cannabis cultivators wanting to build and grow in a large-scale facility in order to expand their enterprise. Approval of the cultivation license allows the company to reasonably project completion of its initial first harvest and commence sales from the crop during First Quarter 2023 resulting in estimated 12 month revenues of $30 million.お知らせ • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 13CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/12/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/31/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 11CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma.CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma on February 10, 2022. The purchase will be completed via a secured note and will include the transfer of licenses. The transaction is expected to close prior to March 31, 2022.お知らせ • Jun 09An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million.An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million on June 8, 2021. The proceeds of the sale will provide working capital, allowing the facility to become production ready in a short period of time. Senior management unanimously agreed a sale was most beneficial for the company and its stakeholders. The deal is expected to close on June 30, 2021.お知らせ • Apr 03CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2021, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 29CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million on January 18, 2021. The purchase price is subject to adjustments. CannaPharmaRX will pay the purchase price for the facility which means the sum of: (i) CAD 12 million and (ii) the CannaPharmaRX share of the option purchase price, not including goods and services tax. The payment schedule for the purchase price will be a deposit of CAD 0.1 million will be paid on execution of the agreement, CAD 5.9 million, plus 50% of the share of the option purchase price, plus the deposit, together with any goods and services tax thereon, subject to adjustments as hereinafter described, shall be paid to the seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the share of the option purchase price, together with any goods and services tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million together with any goods and services tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to satisfaction of due diligence, board approval and certain closing conditions. The transaction is expected to close in February 2021.お知らせ • Jan 13CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million on January 7, 2021. The company will pay the “Purchase Price” for the facility which means the sum of: (i) CAD 12 million and (ii) the Purchaser’s Share of the Option Purchase Price, not including Goods and Services Tax. The payment schedule for the Purchase Price will be a deposit of CAD 0.1 million paid on execution of the PSA, the CAD 5.9 million, plus 50% of the Purchaser’s Share of the Option Purchase Price, plus the deposit, together with any Goods and Services Tax thereon, subject to adjustments as hereinafter described, shall be paid to the Seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the Purchaser’s Share of the Option Purchase Price, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to certain closing conditions and is scheduled to close in February 2021.お知らせ • Aug 19CannaPharmaRX, Inc. announced that it has received $3 million in funding from Triton Funds LLCCannaPharmaRX, Inc. (OTCPK:CPMD) announced that it has received $3,000,000 in a round of funding from new investor Triton Funds LLC on August 18, 2020.お知らせ • Aug 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/14/2020, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 07CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million on June 24, 2020. The acquisition is anticipated to close during the next 45 days, subject to CannapharmaRx receiving appropriate funding. Bennett J. Yankowitz of Shumaker Mallory LLP acted as legal advisor to Bristol, Joshua D. Brinen of Brinen & Associates, LLC acted as legal advisor to CannaPharmaRX.株主還元CPMDUS PharmaceuticalsUS 市場7D-18.9%1.4%-0.3%1Y-9.1%34.5%24.1%株主還元を見る業界別リターン: CPMD過去 1 年間で34.5 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: CPMDは、過去 1 年間で24.1 % のリターンを上げたUS市場を下回りました。価格変動Is CPMD's price volatile compared to industry and market?CPMD volatilityCPMD Average Weekly Movement25.9%Pharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: CPMDの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CPMDの 週次ボラティリティ は過去 1 年間で39%から26%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a26Constantine Nkafuwww.cannapharmarx.comCannaPharmaRX, Inc.はカナダで大麻栽培施設の買収、開発、運営に従事。乾燥大麻フラワーを生産・販売。本社はカナダのカルガリー。もっと見るCannaPharmaRX, Inc. 基礎のまとめCannaPharmaRX の収益と売上を時価総額と比較するとどうか。CPMD 基礎統計学時価総額US$2.02m収益（TTM）-US$11.13m売上高(TTM)US$1.36m1.5xP/Sレシオ-0.2xPER（株価収益率CPMD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CPMD 損益計算書（TTM）収益US$1.36m売上原価US$3.75m売上総利益-US$2.39mその他の費用US$8.74m収益-US$11.13m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.017グロス・マージン-175.34%純利益率-817.19%有利子負債／自己資本比率-48.5%CPMD の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/18 08:24終値2026/05/15 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CannaPharmaRX, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 14Cannapharmarx, Inc. Announces Resignation of Director Rick Orman, Effective January 8, 2026CannaPharmaRX, Inc. announced that on January 8, 2026, Rick Orman informed the Board of Directors of his resignation as a member of the Board effective immediately. Mr. Orman's resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company.
お知らせ • Aug 22Cannapharmarx, Inc. Announces Revenue Guidance for Third Quarter 2025CannaPharmaRX, Inc. announced revenue guidance for third quarter 2025. The company projects revenues of approximately CAD 1,050,000, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate.
お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jun 06CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.
お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/15/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 14Cannapharmarx, Inc. Announces Resignation of Director Rick Orman, Effective January 8, 2026CannaPharmaRX, Inc. announced that on January 8, 2026, Rick Orman informed the Board of Directors of his resignation as a member of the Board effective immediately. Mr. Orman's resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company.
お知らせ • Aug 22Cannapharmarx, Inc. Announces Revenue Guidance for Third Quarter 2025CannaPharmaRX, Inc. announced revenue guidance for third quarter 2025. The company projects revenues of approximately CAD 1,050,000, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate.
お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jun 06CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.
お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/15/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 28CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/27/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2023, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 15CannaPharmaRX, Inc. Announces Executive ChangesEffective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc. effective June 1, 2023. There was no disagreement between and Mr. Cassels on any matter related to operations, policies or practices that led to Mr. Cassels’s replacement as CFO. Effective October 13, 2023, Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer. Mr. Foeste has consented to such appointment. Mr. Foeste is the founder and Managing Partner of Invictus Accounting Group LLP and has significant executive, director, finance, and public company compliance experience across a number of industry sectors including cannabis and nutraceuticals. Prior to Invictus, Mr. Foeste was in senior finance and accounting roles at TSX, TSXV, and NYSE listed issuers, and earned his CPA at Deloitte and a boutique tax advisory firm.
お知らせ • Aug 26CannaPharmaRx Expands Board of DirectorsCannaPharmaRX, Inc. announced that it has expanded its board of directors from three seats to five. The board deemed this expansion was in the best interest of the corporation as it coincides with an expansion of operations. The following person(s) were elected to the Board to fill the newly created directorships until the next annual meeting of stockholders of the corporation: Mr. Anthony Panek, age 38, is a corporate mergers and acquisitions attorney and venture capital investor with expertise in capital raising formation and growing businesses. He has worked with private equity and venture capital funds to allocate capital to emerging growth companies and works with emerging growth companies, both public and private, to raise capital and acquire assets and corporate talent. He has been an investor in many emerging growth companies and private funds investing in similar companies. He works with companies from a business and legal perspective to navigate and manage growth challenges facing emerging growth companies and helping companies complying with their SEC reporting obligations. He completed the Venture Capital Certificate Program at Startup@Berkeley Law. Mr. Panek was selected to serve on the Company's Board based upon his experience as an attorney and venture capital and private equity investor helping emerging companies raise capital, comply with SEC reporting and governance requirements, and his work with other cannabis companies. Mr. Adam Mindle, age 52, is a transactional attorney with extensive experience in structuring, negotiating and documenting sophisticated joint ventures, secured financing and mergers and acquisitions related to real estate, healthcare and technology companies. In 2010, Mr. Mindle co-founded Greystone Law Group LLP. Prior to co-founding Greystone Law Group LLP, Mr. Mindle was a partner in the Los Angeles officer of Orrick, Herrington & Sutcliffe LLP. Mr. Mindle is a veteran authority on real estate, finance and corporate transactions having represented real estate developers, private equity funds, pension funds, REITs, public and private companies and institutional lenders in connection with the acquisition and disposition of real estate assets, secured financing and joint ventures. During his three-decade career, Mr. Mindle has guided numerous start-up companies, mature organizations, pension funds, REITs and other public and private companies through a myriad of sophisticated transactions valued in billions of dollars. The third and final board position will look to be filled in the near future. Mark Branson has chosen to step down from his current position on the Board.
お知らせ • Jun 24CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.
お知らせ • Jan 12CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million ExpectedCannaPharmaRx, Inc. announced that it has received its CRA license. A company can start producing cannabis products after receiving licensing from both the CRA and Health Canada. CannaPharmaRx can now begin business activities relating to the production and sale of cannabis. The license is valid for up to two years. CannaPharmaRx is now authorized to grow cannabis and sell wholesale to other licensed producers throughout Canada. The CRA oversees regulation of cannabis products including the production, possession, removal, sale and distribution of cannabis as well as impose proper excise duties and taxes on cannabis products. Now that both licenses are approved the company anticipates completing the first harvest during the current quarter with estimated annual revenue over $30 million.
お知らせ • Dec 22+ 2 more updatesCannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 MillionCannaPharmaRx, Inc. announced Health Canada has issued a cultivation license to the Company. As a result, CannaPharmaRx may now legally grow cannabis and sell its crop to other licensed producers and licensed wholesalers throughout Canada. Health Canada is the department of the federal government of Canada responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. The new license, denominated LIC-3JCQW6DIU0, is among the final major steps prior to production. This type of standard cultivation license is a prerequisite for licensed cannabis cultivators wanting to build and grow in a large-scale facility in order to expand their enterprise. Approval of the cultivation license allows the company to reasonably project completion of its initial first harvest and commence sales from the crop during First Quarter 2023 resulting in estimated 12 month revenues of $30 million.
お知らせ • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 13CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/12/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/31/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 11CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma.CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma on February 10, 2022. The purchase will be completed via a secured note and will include the transfer of licenses. The transaction is expected to close prior to March 31, 2022.
お知らせ • Jun 09An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million.An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million on June 8, 2021. The proceeds of the sale will provide working capital, allowing the facility to become production ready in a short period of time. Senior management unanimously agreed a sale was most beneficial for the company and its stakeholders. The deal is expected to close on June 30, 2021.
お知らせ • Apr 03CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2021, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 29CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million on January 18, 2021. The purchase price is subject to adjustments. CannaPharmaRX will pay the purchase price for the facility which means the sum of: (i) CAD 12 million and (ii) the CannaPharmaRX share of the option purchase price, not including goods and services tax. The payment schedule for the purchase price will be a deposit of CAD 0.1 million will be paid on execution of the agreement, CAD 5.9 million, plus 50% of the share of the option purchase price, plus the deposit, together with any goods and services tax thereon, subject to adjustments as hereinafter described, shall be paid to the seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the share of the option purchase price, together with any goods and services tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million together with any goods and services tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to satisfaction of due diligence, board approval and certain closing conditions. The transaction is expected to close in February 2021.
お知らせ • Jan 13CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million on January 7, 2021. The company will pay the “Purchase Price” for the facility which means the sum of: (i) CAD 12 million and (ii) the Purchaser’s Share of the Option Purchase Price, not including Goods and Services Tax. The payment schedule for the Purchase Price will be a deposit of CAD 0.1 million paid on execution of the PSA, the CAD 5.9 million, plus 50% of the Purchaser’s Share of the Option Purchase Price, plus the deposit, together with any Goods and Services Tax thereon, subject to adjustments as hereinafter described, shall be paid to the Seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the Purchaser’s Share of the Option Purchase Price, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to certain closing conditions and is scheduled to close in February 2021.
お知らせ • Aug 19CannaPharmaRX, Inc. announced that it has received $3 million in funding from Triton Funds LLCCannaPharmaRX, Inc. (OTCPK:CPMD) announced that it has received $3,000,000 in a round of funding from new investor Triton Funds LLC on August 18, 2020.
お知らせ • Aug 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/14/2020, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 07CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million on June 24, 2020. The acquisition is anticipated to close during the next 45 days, subject to CannapharmaRx receiving appropriate funding. Bennett J. Yankowitz of Shumaker Mallory LLP acted as legal advisor to Bristol, Joshua D. Brinen of Brinen & Associates, LLC acted as legal advisor to CannaPharmaRX.
